3647 results for «819»

Filter By

3647 results

Left main complications - Part 2

21 May 2026 – From EuroPCR 2026

This session covers intricate complications involving the left main coronary artery (LMCA), highlighting cases of catheter-induced dissections, challenges in chronic total occlusion (CTO) PCI, and rare scenarios such as stent entrapment and complex re-interventions. Emphasis is placed on the critical utility of intravascular ultrasound (IVUS) and...

Novel indications for DCB

21 May 2026 – From EuroPCR 2026

This session reviews emerging clinical applications for drug-coated balloons (DCB) beyond traditional indications. It covers outcomes in venous stenosis, aorto-ostial lesions, and coronary bifurcation disease, comparing DCB strategies with drug-eluting stents and highlighting recent clinical trial findings.

Primary PCI dilemmas: when imaging saves the day

21 May 2026 – From EuroPCR 2026

This session highlights the pivotal role of imaging in resolving dilemmas during primary percutaneous coronary intervention (PCI). It presents complex cases illustrating challenges such as coronary compression, thrombus burden in large vessels, and culprit lesion identification, including the use of high-definition intravascular ultrasound (HD-IVUS) to reclassify...

Optimising TAVI care pathways

21 May 2026 – From EuroPCR 2026

This session examines innovations in TAVI care pathways aimed at improving patient outcomes and healthcare efficiency. Topics include large-scale transatlantic data on day-case TAVI, standardized ECG conduction algorithms reducing hospital stay, nurse-led structured pathways, feasibility of very early discharge, and urgent outpatient TAVI for severe aortic...

Vesalio announces FDA Approval of the NeVa VS™ to treat cerebral vasospasm after aneurysmal rupture

15 Sep 2022

Foldax announces positive one-year data on TRIA Mitral Valve

27 Jun 2025

Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial

07 Apr 2024

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Nicola Ryan

Author

Nicola Ryan
Ali Nazmi Calik

Author

Ali Nazmi Calik
REDUCE-AMI: Long-term beta-blocker treatment after AMI and preserved LVEF
Didn’t find what you were looking for?